Frederick Berro Rivera, Sung Whoy Cha, Michelle Capahi Varona, Elaiza Marie Fernandez Co, John Vincent Magalong, John Paul Aparece, Diana De Oliveira-Gomes, Gurleen Kaur, Martha Gulati
BACKGROUND: Studies reporting collective and comprehensive data on plaque regression of different lipid-lowering therapies (LLTs) are limited. OBJECTIVES: We evaluated plaque regression of LLTs based on multiple markers and performed subgroup analyses based on LLT type and post-treatment LDL-C levels. METHODS: A literature search was performed to identify studies assessing plaque regression from LLTs. The following LLTs groups were included: High-intensity statin (HIS), HIS+ eicosapentaenoic acid (EPA), HIS + ezetimibe, Low-intensity statin (LIS), LIS + EPA, LIS + Ezetimibe, and PCSK9 inhibitors...
June 2024: American journal of preventive cardiology